Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | terminated | Phase 1 / Phase 2 | 1 | Baylor College of MedicineOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 16, 2020 | clinicaltrials |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | terminated | Phase 1 | 5 | University of UtahOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer | terminated | Phase 1 / Phase 2 | 24 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | terminated | Phase 1 | 16 | Celldex TherapeuticsINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | terminated | Phase 1 / Phase 2 | 104 | Heat BiologicsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT00005655 | Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer | terminated | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | terminated | Phase 1 | 6 | Virginia Commonwealth UniversityOTHER | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01342172 | Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT00923390 | Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT01457131 | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 1 | 17 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03106610 | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy | terminated | Phase 1 / Phase 2 | 12 | AEterna ZentarisINDUSTRY | 1 | Mar 15, 2018 | clinicaltrials |
| NCT01573156 | Vascular Targeted Photodynamic Therapy T1a Renal Tumours(KCM201) | terminated | Phase 1 / Phase 2 | 5 | University of OxfordOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00623077 | MT2004-30: Tomotherapy for Solid Tumors | terminated | Phase 1 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | terminated | Phase 1 | 26 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02925533 | Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | terminated | Phase 1 | 1 | Mark Pomerantz, MDOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma(5-AZ) | terminated | Phase 1 / Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01155791 | Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | terminated | Phase 1 | 2 | Sandy SrinivasOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer | terminated | Phase 1 | 2 | Stanford UniversityOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) | terminated | Phase 1 / Phase 2 | 1 | Duke UniversityOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors | terminated | Phase 1 | 3 | Beth Israel Medical CenterOTHER | 1 | Jan 9, 2017 | clinicaltrials |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | terminated | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | terminated | Phase 1 | 7 | University of PittsburghOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT00522249 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | terminated | Phase 1 / Phase 2 | 10 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00747305 | Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery | terminated | Phase 1 | 17 | Harry DrabkinOTHER | 1 | Oct 22, 2015 | clinicaltrials |
| NCT00589550 | PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 | 1 | Thomas OlenckiOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | terminated | Phase 1 | 12 | BayerINDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | terminated | Phase 1 | 4 | Seagen Inc.INDUSTRY | 1 | Jan 28, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2020source: clinicaltrials